Berlin-based ProBioGen has closed a deal with Asahi Kasei Pharma (TYO:2502) to collaborate on biologics. The German company said it will use its proprietary cell line development platform and transposase technology to support Tokyo-based Asahi Kasei’s biologics pipeline development.
“We are enchanted to work with Asahi Kasei Pharma on one of their key projects and are convinced that we can make a difference by applying our inventive technologies,” said Dr. Gabriele Schneider, chief business officer at ProBioGen in prepared remarks.
Last month, ProBioGen announced that it had signed a similar agreement with Ladenburg, Germany-based Heidelberg Pharma related to antibody targeted amanitin conjugate molecules.
The company also announced that Schlieren, Switzerland-based ImmunOs Therapeutics was using ProBioGen’s proprietary pathway modulator technology to boost the protein yield of candidates in that company’s pipeline of novel complex recombinant proteins.
Tell Us What You Think!